<DOC>
	<DOCNO>NCT00030225</DOCNO>
	<brief_summary>The purpose study determine treatment ELAD Bioartificial Liver Assist Device beneficial patient Acute Liver Failure either bridge liver transplant bridge native liver recovery .</brief_summary>
	<brief_title>Phase 2 Evaluation ELAD System Management Acute Liver Failure</brief_title>
	<detailed_description>Current treatment modality Acute Liver Failure still carry unacceptable morbidity mortality . It hop intervene ELAD patient opportunity bridge transplant avoid transplantation native liver recover .</detailed_description>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>Inclusion criterion : Clinical diagnosis Fulminant Hepatic Failure encephalopathy , coagulopathy Weight le 40 kilogram Not list organ transplant , medical contraindication transplant Listed organ transplant stud entry History jaundice great 28 day screen Liver dysfunction due trauma Concomitant serious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Fulminant Hepatic Failure</keyword>
</DOC>